IVA Inventiva S.A.

3.471USD3.165 EUR · EPA+8.39%Mkt Cap: 830.01M USDP/E: —

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in F…

Institutional holders7 on file

Key Statistics

Company
Market Cap830.01M USD
Enterprise Value790.23M USD
Revenue (TTM)2.69M USD
Gross Profit2.11M USD
Net Income (TTM)-388.42M USD
Revenue/Share0.0099 USD
Last Price3.471 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees87
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0013233012
Valuation
P/E (Trailing)—
P/E (Forward)-9.84
PEG—
EV/EBITDA-4.83
EV/Revenue293.36
P/S308.13
P/B12.66
EPS (TTM)-0.58 USD
EPS (Forward)-0.35 USD
52W Range
2.81916% of range6.800
52W High6.800 USD
52W Low2.819 USD
Profitability
Gross Margin78.26%
Oper. Margin-5980.94%
EBITDA Margin0.00%
Profit Margin-7899.58%
ROE1241.63%
ROA-141.93%
ROIC—
ROCE-77.20%
Growth
Revenue Growth-76.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-115.04M USD
CapEx (TTM)270.91K USD
FCF Margin-4727.97%
FCF Yield-15.34%
Net Debt-29.98M USD
Net Debt/EBITDA0.18
Net Debt/FCF—
Balance Sheet
Debt/Equity-2.10
Current Ratio3.81
Quick Ratio2.73
Book Value/Sh0.27 USD
Cash/Share0.77 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)10.15 USD
Upside (mean)+192.4%
Target Range6.800 USD – 16.98 USD
6.800+192.4% to mean16.98
# Analysts5
Ownership
Shares Out.239.10M
Float179.98M
Insiders12.52%
Institutions49.22%
Technical
SMA 503.442 (+0.9%)
SMA 2004.408 (-21.2%)
Beta0.97
S&P 52W Chg12.00%
Avg Vol (30d)555.01K
Avg Vol (10d)498.68K
Technical Indicators
RSI (14)48.4
MACD-0.0087
MACD Signal0.0352
MACD Hist.-0.0439
BB Upper4.039 USD
BB Middle3.614 USD
BB Lower3.190 USD
BB Width23.50%
ATR (14)0.2845 USD
Vol Ratio (20d)1.03x

About Inventiva (EPA: IVA)

›

Inventiva (EPA: IVA) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 87 employees.

The shares were at 3.165 EUR on 19 November 2026, down 8.7% over 52 weeks. Its 52-week range is 2.570 EUR to 6.200 EUR: the price is 49.0% below the high and 23.2% above the low.

Its market capitalisation is 756.76M EUR.

Inventiva reports revenue down 76.7% year over year.

It holds more cash than debt, a net cash position of 27.34M EUR. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 5 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 9.256 EUR is 192.4% above the current price. The next earnings report is expected on 1 April 2027.